Merck

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Merck forges $2.13B deal with Chinese biotech for experimental cancer drug (öffnet in neuem Tab)

  ROI-NJ · 02.10.2026

• Merck inks $2.13B deal for experimental cancer drug (öffnet in neuem Tab)

  NJBIZ · 01.10.2026

• 
  Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study (öffnet in neuem Tab)

  Zacks · 01.10.2026

• 
  Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The Buzz (öffnet in neuem Tab)

  Investor's Business Daily · 01.10.2026

• ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? (öffnet in neuem Tab)

  Zacks · 01.10.2026

• Merck to Hold Third-Quarter 2026 Sales and Earnings Conference Call Oct. 29 (öffnet in neuem Tab)

  Business Wire · 01.10.2026

• Moderna, Merck Rally On Cancer Vaccine Promise. But Is The Multi-Billion-Dollar Hype Real? (öffnet in neuem Tab)

  Investor's Business Daily · 01.10.2026

• Merck (MRK) Stock Still Looks Reasonable On Its 110% Run (öffnet in neuem Tab)

  Simply Wall Street · 30.09.2026

• Why Merck (MRK) Dipped More Than Broader Market Today (öffnet in neuem Tab)

  Yahoo! Finance Canada · 30.09.2026

• Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline (öffnet in neuem Tab)

  Barrons.com · 30.09.2026

• After Moderna's Dizzying Rally, It's Time To Sell, Says Analyst (öffnet in neuem Tab)

  Investor's Business Daily · 30.09.2026

• Top Analyst Reports for Apple, Microsoft & Broadcom (öffnet in neuem Tab)

  Zacks · 30.09.2026

• Was The Run In JNJ Stock Hiding In Plain Sight? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• Merck Says Investigational Skin Therapy Shows Potential (öffnet in neuem Tab)

  Benzinga · 30.09.2026

• Are You Overpaying For Pfizer Stock Versus Its Rivals? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• Merck's experimental skin disease drug succeeds in mid-stage study (öffnet in neuem Tab)

  Reuters · 30.09.2026

• Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now? (öffnet in neuem Tab)

  Zacks · 30.09.2026

• What Is Merck Stock's Biggest Opportunity? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• What Is Merck Stock’s Biggest Opportunity? (öffnet in neuem Tab)

  Trefis · 30.09.2026

• Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat (öffnet in neuem Tab)

  Yahoo Finance · 30.09.2026

• Merck Enters $2.13 Billion License Deal With SciBrunch for Preclinical KRAS G12D Inhibitor (öffnet in neuem Tab)

  biobuzz.io · 30.09.2026

• 3 Cash-Producing Stocks with Open Questions (öffnet in neuem Tab)

  StockStory · 30.09.2026

• Merck says experimental skin disease drug meets main goal in mid-stage study (öffnet in neuem Tab)

  yahoo.com · 30.09.2026

• SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. (öffnet in neuem Tab)

  Motley Fool · 30.09.2026

• Merck shows off mid-stage win for Prometheus drug in painful skin disease (öffnet in neuem Tab)

  Endpoints News · 30.09.2026

• Merck pulls antibiotic for multidrug-resistant infections from US market (öffnet in neuem Tab)

  CIDRAP · 29.09.2026

• AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck (öffnet in neuem Tab)

  Investor's Business Daily · 29.09.2026

• Merck Stock Slips 1.5% as $400 Million Buys KRAS Rights (öffnet in neuem Tab)

  Yahoo Finance · 29.09.2026

• Unpacking Q2 Earnings: Merck (NYSE:MRK) In The Context Of Other Branded Pharmaceuticals Stocks (öffnet in neuem Tab)

  StockStory · 29.09.2026

• Merck Animal Health expands SenseHub dairy monitoring capability (öffnet in neuem Tab)

  Feedstuffs · 29.09.2026